Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients' subgroups
…, F Cozzi, A Spinella, E Visalli, Y Dal Bosco… - Journal of …, 2021 - Elsevier
Autoimmune systemic diseases (ASD) may show impaired immunogenicity to COVID-19
vaccines. Our prospective observational multicenter study aimed to evaluate the …
vaccines. Our prospective observational multicenter study aimed to evaluate the …
Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases
…, F Cozzi, A Spinella, E Visalli, Y Dal Bosco… - Journal of …, 2022 - Elsevier
Autoimmune systemic diseases (ASD) show impaired immunogenicity to COVID-19 vaccines.
Our prospective observational multicenter study aimed at evaluating the seroconversion …
Our prospective observational multicenter study aimed at evaluating the seroconversion …
Present and future of biologic drugs in primary Sjögren's syndrome
D Sambataro, G Sambataro, Y Dal Bosco… - Expert Opinion on …, 2017 - Taylor & Francis
Introduction: Primary Sjögren’s (pSS) syndrome is a chronic, autoimmune, and systemic
disease characterized by xerostomia, xerophthalmia, muscle pain and fatigue. The disease may …
disease characterized by xerostomia, xerophthalmia, muscle pain and fatigue. The disease may …
Covid-19 and rheumatic autoimmune systemic diseases: role of pre-existing lung involvement and ongoing treatments
…, E Visalli, Y Dal Bosco… - Current …, 2021 - ingentaconnect.com
Background: The Covid-19 pandemic may have a deleterious impact on patients with
autoimmune systemic diseases (ASD) due to their deep immune-system alterations. Objective: …
autoimmune systemic diseases (ASD) due to their deep immune-system alterations. Objective: …
Heart valve abnormalities in systemic sclerosis patients: a multicenter cohort study and review of the literature
M Colaci, C Schinocca, Y Dal Bosco… - JCR: Journal of …, 2022 - journals.lww.com
Background Systemic sclerosis (SSc) is a chronic autoimmune disease that is characterized
by vasculopathy and fibrosis of the skin and visceral organs. Heart valve diseases are …
by vasculopathy and fibrosis of the skin and visceral organs. Heart valve diseases are …
[HTML][HTML] Long-Term Retention Rate of Tofacitinib in Rheumatoid Arthritis: An Italian Multicenter Retrospective Cohort Study
…, F Serale, R Foti, G Amato, F De Lucia, Y Dal Bosco… - Medicina, 2023 - mdpi.com
Background: Tofacitinib (TOFA) was the first Janus kinase inhibitor (JAKi) to be approved for
the treatment of rheumatoid arthritis (RA). However, data on the retention rate of TOFA …
the treatment of rheumatoid arthritis (RA). However, data on the retention rate of TOFA …
[HTML][HTML] Clinical and histopathological features of scleroderma-like disorders: an update
R Foti, R De Pasquale, Y Dal Bosco, E Visalli, G Amato… - Medicina, 2021 - mdpi.com
Scleroderma-like disorders include a set of entities involving cutis, subcutis and, sometimes,
even muscular tissue, caused by several pathogenetic mechanisms responsible for different …
even muscular tissue, caused by several pathogenetic mechanisms responsible for different …
[HTML][HTML] Telemedicine in the management of patients with rheumatic disease during COVID-19 pandemic: incidence of psychiatric disorders and Fibromyalgia in …
R Foti, G Amato, Y Dal Bosco, A Longo… - International Journal of …, 2022 - mdpi.com
The management of patients with immuno-rheumatological diseases has profoundly changed
during the COVID-19 pandemic and telemedicine has played an important role in the …
during the COVID-19 pandemic and telemedicine has played an important role in the …
[HTML][HTML] Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with …
…, R Brittelli, V Aiello, Y Dal Bosco… - Journal of Translational …, 2023 - Elsevier
Introduction The impact of COVID-19 pandemic represents a serious challenge for ‘frail’
patients' populations with inflammatory autoimmune systemic diseases such as systemic …
patients' populations with inflammatory autoimmune systemic diseases such as systemic …
Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study
…, E Lubrano, L Costa, Y Dal Bosco… - Therapeutic …, 2022 - journals.sagepub.com
Objectives: To evaluate, in a multicentric Italian cohort of axial spondyloarthritis (axSpA)
patients on Secukinumab (SEC) followed for 24 months: (1) the long-term effectiveness and …
patients on Secukinumab (SEC) followed for 24 months: (1) the long-term effectiveness and …